Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Index (AUT100)
4/16/2026, 12:00:00 AM
Sold the gene-therapy asset botaretigene sparoparvovec (bota-vec) to MeiraGTx on 2026-04-16 as part of a portfolio management strategy. Low importance as the divestiture of a single asset is estimated to have a 1-5% price impact; expected.
Korean Translation
2026년 4월 16일 유전자 치료 자산 보타레티진 스파로파르보벡(보타-벡)을 MeiraGTx에 매각함. 단일 자산 매각은 1-5% 수준의 주가 영향이 예상되어 'Low'로 분류함; 예상됨.
Related Recent Events
Cloudflare Inc (NET) · Other
Cloudflare is scheduled to host an Investor Day on June 9, 2026; a >=5% price impact is estimated as the company provides strategic updates scheduled.
6/9/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic will report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026 (High importance estimated due to potential volatility from annual results), scheduled.
6/3/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Q2 2026 earnings release is scheduled.
6/2/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Other
Axon's Annual Meeting of Shareholders on 2026-05-28 where director Matthew McBrady will not seek re-election, which is estimated to have low importance as board changes are common, is scheduled.
5/28/2026, 12:00:00 AM